MEK1 Antibody (YA5208)
(Synonyms: AA589381; Dual specificity mitogen-activated protein kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 2; ERK activator kinase 1; ERK activator kinase 2; FLJ26075; MAP kinase kinase 1; MAP kinase kinase 2; MAP2K1; MAP2K2; MAPK/ERK kinase 1; MAPK/ERK kinase 2; MAPKK 1; MAPKK1; MAPKK2; MEK 1; MEKK1; Mitogen activated protein kinase kinase 1; Mitogen activated protein kinase kinase 2; Mitogen-activated protein kinase kinase 2, p45; MK2; MKK 1; MKK 2; MKK1; MKK2; MP2K1_HUMAN; PRKMK 1; PRKMK 2; Prkmk1; Prkmk2; protein kinase, mitogen-activated, kinase 1; MAP kinase kinase 1; Protein kinase, mitogen-activated, kinase 1; Protein kinase, mitogen-activated, kinase 2.)MEK1 Antibody (YA5208) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to MEK1.
-
Host:
Mouse
-
Application:
WB
-
Reactivity :
Human
-
Formulation:
Supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
|---|---|
| Dilution Ratio | 1:500 |
Product Details
MEK1 Antibody (YA5208) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to MEK1.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 45 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
Recombinant human MEK1 protein.
affinity chromatography.
Non-conjugated
Unmodified
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
MEK1 is a MAP kinase or ERK kinase that phosphorylates the ERK gene product and acts as an immediate upstream activator of ERK signaling[1][2]. Mechanistically, MEK1 and MEK2 phosphorylate and activate ERK1/ERK2, positioning MEK proteins as pathway gatekeepers in the RAS-RAF-MEK-ERK cascade[3][4]. This cascade regulates cell proliferation, differentiation, survival, invasion, and other ERK-dependent cellular responses[3][5]. In disease models, ERK pathway activation is prominent in cancers driven by receptor tyrosine kinase, RAS, BRAF, CRAF, MEK1, or MEK2 alterations, which promote growth factor-independent ERK1/2 activation[5]. Compared with MEK2, MEK1 shares the same ERK substrates, but Mek1- embryos die from placental defects whereas Mek2- mice survive, indicating isoform-related developmental differences and functional redundancy controlled by total MEK protein level[4]. Structurally, MEK1 and MEK2 are closely related dual-specificity tyrosine/threonine kinases with a hydrophobic allosteric pocket adjacent to the ATP-binding site[6][5]. For experimental applications, PD098059 selectively inhibited MEK without significant inhibition of MAPK itself, and allosteric MEK blockade suppressed colon tumor growth in vivo[7][8].
-
Subcellular Localization
P36507: Cytoplasm; Membrane; Peripheral membrane protein
Q02750: Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cytoplasm, cytoskeleton, microtubule organizing center, spindle pole body; Cytoplasm; Nucleus; Membrane; Peripheral membrane protein -
Expression
Tissue_specificity: Q02750: Widely expressed, with extremely low levels in brain -
Isoforms & Post-Translational Modification
Q02750 has 2 isomers: Q02750-1: 43439 Da (predicted); Q02750-2: 40764 Da (predicted).
Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinase kinases (BRAF or MEKK1) positively regulates kinase activity (PubMed:29433126, PubMed:8131746). Also phosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK (PubMed:16129686). MAPK1/ERK2 phosphorylation of Thr-292 occurs in response to cellular adhesion and leads to inhibition of Ser-298 phosphorylation by PAK (PubMed:16129686). Autophosphorylated at Ser-218 and Ser-222, autophosphosphorylation is promoted by NEK10 following UV irradiation (PubMed:20956560);(Microbial infection) Acetylation by Yersinia YopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway -
Subunit
P36507: Interacts with MORG1 (By similarity). Interacts with SGK1 (PubMed:19447520). Interacts with KSR1 (PubMed:10409742). Interacts with KSR1 and BRAF; the interaction with KSR1 mediates KSR1-BRAF dimerization (PubMed:29433126). Interacts with GLS (PubMed:22538822)
Q02750: Found in a complex with at least BRAF, HRAS, MAP2K1, MAPK3/ERK1 and RGS14 (By similarity). Forms a heterodimer with MAP2K2/MEK2 (By similarity). Forms heterodimers with KSR2 which further dimerize to form tetramers (By similarity). -
Synonyms
AA589381; Dual specificity mitogen-activated protein kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 2; ERK activator kinase 1; ERK activator kinase 2; FLJ26075; MAP kinase kinase 1; MAP kinase kinase 2; MAP2K1; MAP2K2; MAPK/ERK kinase 1; MAPK/ERK kinase 2; MAPKK 1; MAPKK1; MAPKK2; MEK 1; MEKK1; Mitogen activated protein kinase kinase 1; Mitogen activated protein kinase kinase 2; Mitogen-activated protein kinase kinase 2, p45; MK2; MKK 1; MKK 2; MKK1; MKK2; MP2K1_HUMAN; PRKMK 1; PRKMK 2; Prkmk1; Prkmk2; protein kinase, mitogen-activated, kinase 1; MAP kinase kinase 1; Protein kinase, mitogen-activated, kinase 1; Protein kinase, mitogen-activated, kinase 2.
Documentation
References
[1]. Crews CM, et al. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science. 1992 Oct 16;258(5081):478-80. [Content Brief]
[2]. Zheng CF, et al. Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases. J Biol Chem. 1993 Nov 15;268(32):23933-9. [Content Brief]
[3]. Shaul YD, et al. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta. 2007 Aug;1773(8):1213-26. [Content Brief]
[4]. Aoidi R, et al. Functional redundancy of the kinases MEK1 and MEK2: Rescue of the Mek1 mutant phenotype by Mek2 knock-in reveals a protein threshold effect. Sci Signal. 2016 Jan 26;9(412):ra9. [Content Brief]
[5]. Caunt CJ, et al. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer. 2015 Oct;15(10):577-92. [Content Brief]
[6]. Ohren JF, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol. 2004 Dec;11(12):1192-7. [Content Brief]
[7]. Dudley DT, et al. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7686-9. [Content Brief]
[8]. Sebolt-Leopold JS, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 1999 Jul;5(7):810-6. [Content Brief]
Powered by Bioz
